Lipertance

Amlodipine besilate / perindopril arginine / atorvastatin calcium, the active ingredient in Lipertance, is a combination antihypertensive and lipid‑lowering agent presented as an oral tablet for oral use. It treats essential hypertension and hyperlipidaemia in adult patients. GNH USA supplies Lipertance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipertance is indicated for conditions affecting blood pressure and lipid metabolism. - Essential hypertension: provides additive blood‑pressure reduction. - Hyperlipidaemia (elevated LDL‑cholesterol): lowers LDL‑cholesterol levels. - Cardiovascular risk reduction: decreases the overall risk of cardiovascular events in patients with combined hypertension and dyslipidaemia.

Adverse reactions may occur with Lipertance and should be monitored.

Common Side Effects: - Headache - Peripheral edema - Dizziness - Cough - Muscle pain - Gastrointestinal upset

Serious or Rare Side Effects: - Angioedema - Hepatotoxicity - Rhabdomyolysis - Severe hypotension - Pancreatitis - Anaphylaxis

Before initiating therapy, consider the following precautions. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: adjust therapy in patients with impaired renal function. - Liver enzyme evaluation: monitor hepatic function due to atorvastatin metabolism. - Lipid profile review: assess baseline cholesterol levels and response to treatment. - Concomitant medication review: check for potential drug interactions that may affect efficacy or safety. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lipertance may interact with other medicines; categorize interactions by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole): increase atorvastatin exposure. - Concurrent ACE inhibitors: risk of additive hypotension. - Additional calcium‑channel blockers: may cause excessive vasodilation. - Fibrates combined with atorvastatin: heightened risk of muscle toxicity. - Niacin co‑administration: increased liver toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect. - NSAIDs: can reduce blood‑pressure‑lowering efficacy. - Grapefruit juice: modestly raises atorvastatin levels. - Lithium: ACE inhibition may increase lithium concentrations. - Warfarin: potential alteration of INR values.